QLT PhotoTherapeutics Inc., Sanofi Winthrop Inc. deal

Sanofi will exclusively market QLTIF's Photofrin (porfimer sodium) light-activated drug in the U.S. and the Caribbean. Sanofi also received exclusive rights to Benzoporphyrin derivative and additional light-activated compounds for cancerous and pre-cancerous indications. ...